Beam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 Program [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
The spotlight is on the company's BEAM-302 DNA editing program, with management signaling strong confidence in its technological advantages over competing approaches. In addition, the company has made a strategic decision to delay key data readouts until early 2026 to allow for a more thorough regulatory update. Beam has also chosen to pursue the US market independently, without new partnerships. This clarity in strategy and collective analyst optimism could be shaping how the market values the company right now. Together, these moves come after a volatile twelve months for Beam Therapeutics. The share price has declined over the past year, even as the past three months showed momentum reversing course with a 24% gain. Still, bigger picture challenges remain: multi-year returns are negative and profit metrics are yet to turn around, despite annual revenue growth. This mix of renewed strategic focus and improved recent share performance raises questions about the underlying value dri
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]Seeking Alpha
- Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
- Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]Forbes
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- 11/4/25 - Form 8-K
- BEAM's page on the SEC website